These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 18089718

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment.
    Okajima E, Ozono S, Endo T, Majima T, Tsutsumi M, Fukuda T, Akai H, Denda A, Hirao Y, Okajima E, Nishino H, Nir Z, Konishi Y.
    Jpn J Cancer Res; 1997 Jun; 88(6):543-52. PubMed ID: 9263531
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria.
    Zeng J, Sun Y, Wu K, Li L, Zhang G, Yang Z, Wang Z, Zhang D, Xue Y, Chen Y, Zhu G, Wang X, He D.
    Mol Cancer Ther; 2011 Jan; 10(1):104-16. PubMed ID: 21220495
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis.
    Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, Shimazui T, Akaza H, Yamamoto M.
    Cancer Res; 2004 Sep 15; 64(18):6424-31. PubMed ID: 15374950
    [Abstract] [Full Text] [Related]

  • 29. Vascular endothelial growth factor mRNA levels as a biomarker for short-term N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinogenesis bioassay.
    Wakui S, Mutou T, Takahashi H, Ikegami M, Wanibuchi H, Fukushima S.
    J Appl Toxicol; 2015 Feb 15; 35(2):181-90. PubMed ID: 24888239
    [Abstract] [Full Text] [Related]

  • 30. Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors.
    Grubbs CJ, Juliana MM, Eto I, Casebolt T, Whitaker LM, Canfield GJ, Manczak M, Steele VE, Kelloff GJ.
    Anticancer Res; 1993 Feb 15; 13(1):33-6. PubMed ID: 8476227
    [Abstract] [Full Text] [Related]

  • 31. Enhancement of urinary bladder carcinogenesis by combined treatment with benzyl isothiocyanate and N-butyl-N-(4-hydroxybutyl)nitrosamine in rats after initiation.
    Okazaki K, Umemura T, Imazawa T, Nishikawa A, Masegi T, Hirose M.
    Cancer Sci; 2003 Nov 15; 94(11):948-52. PubMed ID: 14611670
    [Abstract] [Full Text] [Related]

  • 32. Significance of overexpression of metallothionein in mouse urinary bladder focal lesions induced by treatment with N-butyl-N-(4-hydroxybutyl)-nitrosamine.
    Mitsuhashi M, Wanibuchi H, Morimura K, Doi K, Wei M, Wada S, Nakatani T, Fukushima S.
    Cancer Sci; 2003 Dec 15; 94(12):1052-8. PubMed ID: 14662020
    [Abstract] [Full Text] [Related]

  • 33. Simultaneous treatment with benzyl isothiocyanate, a strong bladder promoter, inhibits rat urinary bladder carcinogenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Okazaki K, Yamagishi M, Son HY, Imazawa T, Furukawa F, Nakamura H, Nishikawa A, Masegi T, Hirose M.
    Nutr Cancer; 2002 Dec 15; 42(2):211-6. PubMed ID: 12416262
    [Abstract] [Full Text] [Related]

  • 34. Downregulation of glutathione S-transferase M1 protein in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced mouse bladder carcinogenesis.
    Chuang JJ, Dai YC, Lin YL, Chen YY, Lin WH, Chan HL, Liu YW.
    Toxicol Appl Pharmacol; 2014 Sep 15; 279(3):322-330. PubMed ID: 24998975
    [Abstract] [Full Text] [Related]

  • 35. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder.
    Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL.
    Carcinogenesis; 1996 Jul 15; 17(7):1435-8. PubMed ID: 8706245
    [Abstract] [Full Text] [Related]

  • 36. DNA cytophotometric and histological analysis of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced precancerous lesions of the bladder urothelium.
    Dahm HH, von der Haar C, Rübben H.
    J Cancer Res Clin Oncol; 2016 Jun 15; 142(6):1253-60. PubMed ID: 27033373
    [Abstract] [Full Text] [Related]

  • 37. Comparison of uroplakin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats and mice.
    Ogawa K, St John M, Luiza de Oliveira M, Arnold L, Shirai T, Sun TT, Cohen SM.
    Toxicol Pathol; 1999 Jun 15; 27(6):645-51. PubMed ID: 10588545
    [Abstract] [Full Text] [Related]

  • 38. Lack of promotion of N-butyl-N-(4-hydroxybutyl)nitrosamine-initiated urinary bladder carcinogenesis in mice by rat cancer promoters.
    Tamano S, Asakawa E, Boomyaphiphat P, Masui T, Fukushima S.
    Teratog Carcinog Mutagen; 1993 Jun 15; 13(2):89-96. PubMed ID: 8102212
    [Abstract] [Full Text] [Related]

  • 39. Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.
    Lubet RA, Scheiman JM, Bode A, White J, Minasian L, Juliana MM, Boring DL, Steele VE, Grubbs CJ.
    Cancer Prev Res (Phila); 2015 Apr 15; 8(4):296-302. PubMed ID: 25762530
    [Abstract] [Full Text] [Related]

  • 40. Chemoprevention of urinary bladder carcinogenesis by the natural phenolic compound protocatechuic acid in rats.
    Hirose Y, Tanaka T, Kawamori T, Ohnishi M, Makita H, Mori H, Satoh K, Hara A.
    Carcinogenesis; 1995 Oct 15; 16(10):2337-42. PubMed ID: 7586132
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.